<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957969</url>
  </required_header>
  <id_info>
    <org_study_id>1.05.8004</org_study_id>
    <nct_id>NCT01957969</nct_id>
  </id_info>
  <brief_title>French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence</brief_title>
  <official_title>French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic International Trading Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic France SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic MCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic International Trading Sarl</source>
  <oversight_info>
    <authority>France: Haute Autorité de la Santé</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to evaluate the utilization in the clinical practice,
      effectiveness, explantation and re-intervention rate, complications and adverse events of
      InterStim system in patients indicated to Sacral Neuromodulation therapy for fecal
      incontinence.

      This study will provide additional data about safety and effectiveness of the usage of
      InterStim system in fecal incontinence environment and at the same time will confirm that
      results from clinical trials can be transposed to clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of implanted patients with a reduction of at least 50% of incontinence episodes per week, compared to baseline.</measure>
    <time_frame>6 months (4-8 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary objective will evaluate the proportion of implanted patients that do not experience any serious adverse event or serious adverse device effect at 4-8 months of follow-up and show a reduction of at least 50% of incontinence episodes per week at the same timeframe, compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of incontinence episodes per week</measure>
    <time_frame>12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of evacuations per week</measure>
    <time_frame>6 months (4-8 months) and 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of urgency episodes per week</measure>
    <time_frame>6 months (4-8 months) and 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention delay</measure>
    <time_frame>3 months (1-4 months), 6 months (5-8 months), 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications and Adverse Events</measure>
    <time_frame>3 months (1-4 months), 6 months (5-8 months), 12 months (9-15 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Incontinence severity</measure>
    <time_frame>3 months (1-4 months), 6 months (5-8 months), 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months (1-4 months), 6 months (5-8 months), 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>6 months (5-8 months) and 12 months (9-15 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Fecal Incontinence</condition>
  <eligibility>
    <study_pop>
      <textblock>
        French subjects affected by fecal incontinence, indicated to sacral neuromodulation
        therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient willing to sign the Data Release Form stating the non opposition to the study
             conduct;

          -  Patient able to understand information given by the investigator in terms of data
             collection and publication;

          -  At least 18 years old or older.

          -  Patient indicated to sacral neuromodulation testing with InterStim® system.

        Exclusion Criteria:

          -  Replacement of an existing sacral neuromodulation system (implanted before inclusion
             period) without any evidence of benefits during a testing period.

          -  Patient unwilling to comply to data collection and publication rules.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Polyclinique du Maine</name>
      <address>
        <city>Laval</city>
        <zip>53010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Peyrot, MD</last_name>
      <email>michel.f.peyrot@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Peyrot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Parc, Pr.</last_name>
      <email>Yann.parc@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Parc, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Matzel KE, Kamm MA, Stosser M, Baeten CG, Christiansen J, Madoff R, Mellgren A, Nicholls RJ, Rius J, Rosen H. Sacral spinal nerve stimulation for faecal incontinence: multicentre study. Lancet. 2004 Apr 17;363(9417):1270-6.</citation>
    <PMID>15094271</PMID>
  </reference>
  <reference>
    <citation>Jarrett ME, Varma JS, Duthie GS, Nicholls RJ, Kamm MA. Sacral nerve stimulation for faecal incontinence in the UK. Br J Surg. 2004 Jun;91(6):755-61.</citation>
    <PMID>15164447</PMID>
  </reference>
  <reference>
    <citation>Uludağ O, Koch SM, van Gemert WG, Dejong CH, Baeten CG. Sacral neuromodulation in patients with fecal incontinence: a single-center study. Dis Colon Rectum. 2004 Aug;47(8):1350-7.</citation>
    <PMID>15484349</PMID>
  </reference>
  <reference>
    <citation>Altomare DF, Rinaldi M, Lobascio P, Marino F, Giuliani RT, Cuccia F. Factors affecting the outcome of temporary sacral nerve stimulation for faecal incontinence. The value of the new tined lead electrode. Colorectal Dis. 2011 Feb;13(2):198-202. doi: 10.1111/j.1463-1318.2009.02088.x.</citation>
    <PMID>19863601</PMID>
  </reference>
  <reference>
    <citation>Mellgren A, Wexner SD, Coller JA, Devroede G, Lerew DR, Madoff RD, Hull T; SNS Study Group. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum. 2011 Sep;54(9):1065-75. doi: 10.1097/DCR.0b013e31822155e9.</citation>
    <PMID>21825885</PMID>
  </reference>
  <reference>
    <citation>Altomare DF, Ratto C, Ganio E, Lolli P, Masin A, Villani RD. Long-term outcome of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum. 2009 Jan;52(1):11-7. doi: 10.1007/DCR.0b013e3181974444.</citation>
    <PMID>19273950</PMID>
  </reference>
  <reference>
    <citation>Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, Ayscue JM, Shobeiri AS, Margolin D, England M, Kaufman H, Snape WJ, Mutlu E, Chua H, Pettit P, Nagle D, Madoff RD, Lerew DR, Mellgren A. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. Ann Surg. 2010 Mar;251(3):441-9. doi: 10.1097/SLA.0b013e3181cf8ed0.</citation>
    <PMID>20160636</PMID>
  </reference>
  <reference>
    <citation>Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. Dis Colon Rectum. 2008 May;51(5):494-502. doi: 10.1007/s10350-007-9103-5. Epub 2008 Feb 16.</citation>
    <PMID>18278532</PMID>
  </reference>
  <reference>
    <citation>Leroi AM, Parc Y, Lehur PA, Mion F, Barth X, Rullier E, Bresler L, Portier G, Michot F; Study Group. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. Ann Surg. 2005 Nov;242(5):662-9.</citation>
    <PMID>16244539</PMID>
  </reference>
  <reference>
    <citation>Tan E, Ngo NT, Darzi A, Shenouda M, Tekkis PP. Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence. Int J Colorectal Dis. 2011 Mar;26(3):275-94. doi: 10.1007/s00384-010-1119-y. Epub 2011 Jan 29.</citation>
    <PMID>21279370</PMID>
  </reference>
  <reference>
    <citation>Matzel KE, Lux P, Heuer S, Besendörfer M, Zhang W. Sacral nerve stimulation for faecal incontinence: long-term outcome. Colorectal Dis. 2009 Jul;11(6):636-41. doi: 10.1111/j.1463-1318.2008.01673.x. Epub 2008 Aug 21.</citation>
    <PMID>18727721</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
